Abstract: Methods of treating irritable bowel syndrome (IBS) include the administration of an effective amount of an anti-microbial decapeptide NH2-Lys-Lys-Val-Val-Phe-Trp-Val-Lys-Phe-Lys-CO NH2 (SEQ ID NO 1) (KSL-W).

Abstract: The present disclosure describes various aspects of various devices, and methods of making and using the devices, for measuring bioimpedance of tissues within a patient's body, such as GI tract tissue. The devices entail using various implementations of capsules or other housings that allow for ingestion or other insertion into a body of the device, equipped with microfabricated sensors and embedded circuitry enabling wireless communication. Among other benefits, this approach addresses a gap in conventional GI tract monitoring devices and methods to non-invasively access the small intestine and directly measure the inflammatory state of intestinal tissue, including ischemia, edema, and mucosal abnormalities.

Abstract: The present disclosure relates generally to fluorescent imaging devices, systems, and methods for an endoscopic procedure, and in particular, indocyanine green (ICG) fluorescence. In some embodiments, a device for fluorescent imaging during an endoscopic procedure may include an attachment connectable to a distal end of an endoscope. The attachment may include a first filter alignable with a light source of the endoscope, and a second filter alignable with an imaging device of the endoscope. The first filter may be positionable such that in a first position the first filter is aligned with the light source, and in a second position the first filter is out of alignment with the light source. The second filter may be positionable such that in a first position the second filter is aligned with the imaging device, and in a second position the second filter is out of alignment with the imaging device.

Abstract: Compositions and methods of use are provided in the treatment of age-associated gastrointestinal dysmotility disorders, along with other pathological manifestations of intestinal dysfunction and dysmotility disorders.

Abstract: Fluorescent imaging systems for performing an endoscopic procedure, such as a retrograde cholangiopancreatography (ERCP) procedure may include a first light source for emitting light in the visible spectrum, or light in the near infrared (NIR) spectrum, or both. A light source bandpass filter may block the emitted light in the visible spectrum, or in the NIR spectrum, or both. A first sensor may be capable of detecting the light in the visible spectrum, or the light in the NIR spectrum, or both. A sensor bandpass filter may block the detected light in the visible spectrum, or in the NIR spectrum, or both. The first or a second light source, or the first or a second sensor, or combinations thereof, may be removably disposed on a duodenoscope.

Abstract: Fluorescent imaging systems for performing an endoscopic procedure, such as a retrograde cholangiopancreatography (ERCP) procedure may include a first light source for emitting light in the visible spectrum, or light in the near infrared (NIR) spectrum, or both. A light source bandpass filter may block the emitted light in the visible spectrum, or in the NIR spectrum, or both. A first sensor may be capable of detecting the light in the visible spectrum, or the light in the NIR spectrum, or both. A sensor bandpass filter may block the detected light in the visible spectrum, or in the NIR spectrum, or both. The first or a second light source, or the first or a second sensor, or combinations thereof, may be removably disposed on a duodenoscope.

Abstract: The present disclosure relates generally to the field of medical devices and establishing access to body passageways. In particular, the present disclosure relates to devices, systems and methods to facilitate entry of an endoscopic accessory tool into and/or through patient-specific anatomies. For example, the devices, systems and methods of the present disclosure may transmit mechanical motion to the distal end of an endoscopic accessory tool to facilitate atraumatic access to tortuous or otherwise restricted anatomies.

Abstract: The present disclosure relates generally to the field of medical devices and establishing access to body passageways. In particular, the present disclosure relates to devices, systems and methods to facilitate entry of an endoscopic accessory tool into and/or through patient-specific anatomies. For example, the devices, systems and methods of the present disclosure may transmit mechanical motion to the distal end of an endoscopic accessory tool to facilitate atraumatic access to tortuous or otherwise restricted anatomies.

Abstract: Described are methods for treating or preventing IBS in subjects by administering molybdenum or a salt thereof to subjects having or prone of getting IBS. The molybdenum has been shown to treat or prevent IBS in subjects administered this agent when compared to reference subjects not administered molybdenum.

Abstract: Death receptor 5 (DR5) agonist compositions and methods for treating pancreatitis have been developed. The compositions include Tumor Necrosis Factor-related apoptosis-inducing ligand (TRAIL), its analogues, and anti-DR5 agonistic antibodies. In certain embodiments, TRAIL analogs and anti-death receptor 5 agonistic antibodies have analgesic and disease modifying effects on the pancreas.

Abstract: The present disclosure relates generally to fluorescent imaging devices, systems, and methods for an endoscopic procedure, and in particular, indocyanine green (ICG) fluorescence. In some embodiments, a device for fluorescent imaging during an endoscopic procedure may include an attachment connectable to a distal end of an endoscope. The attachment may include a first filter alignable with a light source of the endoscope, and a second filter alignable with an imaging device of the endoscope. The first filter may be positionable such that in a first position the first filter is aligned with the light source, and in a second position the first filter is out of alignment with the light source. The second filter may be positionable such that in a first position the second filter is aligned with the imaging device, and in a second position the second filter is out of alignment with the imaging device.

Abstract: The present disclosure relates generally to the field of medical devices and establishing access to body passageways. In particular, the present disclosure relates to devices, systems and methods to facilitate entry of an endoscopic accessory tool into and/or through patient-specific anatomies. For example, the devices, systems and methods of the present disclosure may transmit mechanical motion to the distal end of an endoscopic accessory tool to facilitate atraumatic access to tortuous or otherwise restricted anatomies.

Abstract: Fluorescent imaging systems for performing an endoscopic procedure, such as a retrograde cholangiopancreatography (ERCP) procedure may include a first light source for emitting light in the visible spectrum, or light in the near infrared (NIR) spectrum, or both. A light source bandpass filter may block the emitted light in the visible spectrum, or in the NIR spectrum, or both. A first sensor may be capable of detecting the light in the visible spectrum, or the light in the NIR spectrum, or both. A sensor bandpass filter may block the detected light in the visible spectrum, or in the NIR spectrum, or both. The first or a second light source, or the first or a second sensor, or combinations thereof, may be removably disposed on a duodenoscope.

Abstract: Death receptor 5 (DR5) agonist compositions and methods for treating pancreatitis have been developed. The compositions include Tumor Necrosis Factor-related apoptosis-inducing ligand (TRAIL), its analogues, and anti-DR5 agonistic antibodies. In certain embodiments, TRAIL analogs and anti-death receptor 5 agonistic antibodies have analgesic and disease modifying effects on the pancreas.

Abstract: The present invention provides a method and device for sacral nerve stimulation (SNS) for treatment of disease, such as inflammatory disease. The SNS therapy is automatically adjusted in response to detection of physiological data from the patient.

Abstract: The present invention discloses that diabetic rats showed a reduction in nitrergic relaxation of the gastric, impaired nNOS dimerization, decreased BH4 and GTPCH1 levels and thus, are more susceptible to develop diabetic gastroparesis. The use of tetrahydrobiopterin and its derivatives and sex steroid hormones as disclosed herein provides a novel strategy for therapeutic intervention of diabetic gastroparesis and any other gut-related diseases. Additionally, the present invention also discloses methods to determine risk of developing gastroparesis in an individual that are drawn to detecting variations in the activity and levels of GCH gene and in gene encoding sex steroid hormone receptor.

Abstract: Instruments, systems and methods are provided for performing submucosal medical procedures in a desired area of the digestive tract using endoscopy. Instruments include a safe access needle injection instrument, a submucosal tunneling instrument, a submucosal dissection instrument, a mucosal resection device. Systems include a combination of one or more of such instruments with or without injectable agents. Embodiments of various methods for performing the procedures are also provided.

Abstract: Instruments, systems and methods are provided for performing submucosal medical procedures in a desired area of the digestive tract using endoscopy. Instruments include a safe access needle injection instrument, a submucosal tunneling instrument, a submucosal dissection instrument, a mucosal resection device. Systems include a combination of one or more of such instruments with or without injectable agents. Embodiments of various methods for performing the procedures are also provided.

Abstract: Non-invasive and/or natural orifice procedures, apparatus and methods for modulating the enteric nervous system using one or more energy modalities. A system may include a probe for insertion into a natural orifice (e.g., nasogastrically, orogastrically, nasojejunally) with or without a tube to therapeutically apply energy to modulate one or more portions of the enteric nervous system. The methods described herein may provide energy to stimulate the enteric nervous system to treat disorders such as irritable bowel syndrome, constipation, depression, anxiety and/or to enhance gastric motility, intestinal motility or other neurological responses.

Abstract: The present invention discloses that diabetic rats showed a reduction in nitrergic relaxation of the gastric, impaired nNOS dimerization, decreased BH4 and GTPCH1 levels and thus, are more susceptible to develop diabetic gastroparesis. The use of tetrahydrobiopterin and its derivatives and sex steroid hormones as disclosed herein provides a novel strategy for therapeutic intervention of diabetic gastroparesis and any other gut-related diseases. Additionally, the present invention also discloses methods to determine risk of developing gastroparesis in an individual that are drawn to detecting variations in the activity and levels of GCH gene and in gene encoding sex steroid hormone receptor.